| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,,
* Department of Experimental Medicine and
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and
Department of Medical Biophysics and
Department of Pathology and Laboratory Medicine, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
Vascular endothelial growth factor (VEGF) is a secreted cytokine that plays a major role in the formation and maintenance of the hemopoietic and vascular compartments. VEGF and its receptors, VEGFR-1 and VEGFR-2, have been found to be expressed on subsets of normal and malignant hemopoietic cells, but the role of the individual receptors in hemopoiesis requires further study. Using a VEGFR-2 fusion protein that can be dimerized with a synthetic drug, we were able to specifically examine the effects of VEGFR-2 signaling in hemopoietic cells in vivo. Mice transplanted with bone marrow transduced with this inducible VEGFR-2 fusion protein demonstrated expansion of myeloid cells (Gr-1+, CD11b+). Levels of myeloid progenitors were also increased following VEGFR-2 activation, through autocrine and paracrine mechanisms, as measured by clonogenic progenitor assays. VEGFR-2 activation induced expression of GM-CSF and increased serum levels in vivo. Abrogation of GM-CSF activity, either with neutralizing Abs or by using GM-CSF-null hemopoietic cells, inhibited VEGFR-2-mediated myeloid progenitor activity. Our findings indicate that VEGF signaling through VEGFR-2 promotes myelopoiesis through GM-CSF-dependent and -independent mechanisms.
This article has been cited by other articles:
|
|
 |
|
  M. B. Faries, E. C. Hsueh, X. Ye, M. Hoban, and D. L. Morton Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine Clin. Cancer Res., November 15, 2009; 15(22): 7029 - 7035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Poh, J. M. Bradley, P. Mukherjee, and S. J. Gendler Lack of Muc1-Regulated {beta}-Catenin Stability Results in Aberrant Expansion of CD11b+Gr1+ Myeloid-Derived Suppressor Cells from the Bone Marrow Cancer Res., April 15, 2009; 69(8): 3554 - 3562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function Blood, January 1, 2008; 111(1): 219 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood, July 15, 2007; 110(2): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Larrivee, K. Niessen, I. Pollet, S. Y. Corbel, M. Long, F. M. Rossi, P. L. Olive, and A. Karsan Minimal Contribution of Marrow-Derived Endothelial Precursors to Tumor Vasculature J. Immunol., September 1, 2005; 175(5): 2890 - 2899. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
